About Aditi Ganguly

Aditi is an experienced content developer and financial writer who is passionate about helping investors understand the do's and don'ts of investing.  She has a keen interest in the stock market and has a fundamental approach when analyzing equities.

Aditi's fascination with the stock market began in college, where she majored in Economics, while researching The Great Recession for her thesis.  After graduating, she began her career handling the content requirements for the mutual fund aggregator Groww.  Since then she has become a financial journalist that focuses on writing articles that educate retail investors about the equity markets and the global economy.


Recent Articles By Aditi Ganguly

: FB |  News, Ratings, and Charts

Facebook vs. Snap: Which Stock is a Better Buy?

Facebook (FB) and Snap (SNAP) are among the top 10 most used social media platforms across the world. With recent business developments and favorable financial outlook, these stocks are expected to soar in the upcoming quarters. Aditi gives her take on why SNAP is the better buy.
: EQIX |  News, Ratings, and Charts

4 "Strong Buy" REITs to Buy in October

With interest rates remaining low and the economy gradually recovering from the pandemic-driven slowdown, REITs such as Equinix, Inc. (EQIX), Public Storage (PSA), Extra Space Storage, Inc. (EXR), and Innovative Industrial Properties, Inc. (IIPR) are expected to soar in the upcoming months.
: TSLA |  News, Ratings, and Charts

Tesla vs. NIO: Which Stock is a Better Buy?

Tesla (TSLA) and NIO (NIO) have emerged as key players in the electric vehicle industry. With impressive track record and growth potential, both stocks are valued for money, given their impressive past performance and favorable analyst sentiment. But let’s find out which is the better buy now. 
: AMGN |  News, Ratings, and Charts

4 Game-Changing Biotech Stocks to Buy Right NOW!

Amgen (AMGN), Genmab A/S (GMAB), Seattle Genetics (SGEN), and Alexion Pharmaceuticals (ALXN) are leading biotech companies engaged in developing cancer drugs. As the number of cancer patients rises with each passing day, these stocks should continue to move higher.
: NKE |  News, Ratings, and Charts

3 Stocks That Will Benefit from the Return of College Football

Nike (NKE), Draftkings (DKNG). and Penn National Gaming (PENN) have shown impressive comebacks from losses over the past couple of months. These stocks are expected to gain even more with the return of college football.
: ETSY |  News, Ratings, and Charts

Is Etsy a Great E-Commerce Stock to Buy for 2021?

With people staying at home and the e-commerce sector booming amid the pandemic, Etsy (ETSY) has been witnessing significant business growth. The stock has gained 197.3% year-to-date. Enough short-and-long-term bullishness, impressive past performance, industry strength, and favorable analyst sentiment indicate that there is plenty of upside left in the stock.
: GLD |  News, Ratings, and Charts

4 ETFs to Protect Your Portfolio from a Market CRASH

With rising uncertainty in the stock markets, investing in the SPDR Gold Trust ETF (GLD), iShares Core U.S. Aggregate Bond ETF (AGG), iShares iBoxx $ Investment Grade Corporate Bond (LQD), or the iShares TIPS Bond ETF (TIP) could allow you to hedge your investment risk.
: PTON |  News, Ratings, and Charts

Will Peloton Continue to Soar in 2021?

With the rising popularity of virtual fitness, PTON is well-positioned to keep soaring. Short and long-term bullishness sentiment, its impressive past performance and favorable analyst sentiment point to further upside for the stock.
: ATVI |  News, Ratings, and Charts

3 Video Gaming Stocks to Buy and Hold for 5 Years

Activision Blizzard (ATVI), Take-Two Interactive Software (TTWO), and SciPlay Corporation (SCPL) are well-positioned to benefit from the booming global video game industry. They have some of the best products and are continually growing.
: AMGN |  News, Ratings, and Charts

Amgen vs. Gilead Sciences: Which Stock is a Better Buy?

Amgen (AMGN) and Gilead Sciences (GILD) are two leading bio-pharmaceutical companies. Both have been in headlines this year for their efforts in Covid-treatment. But which is the better buy right now?
Page generated in 1.2853 seconds.